Stiftingtalstraße 14 | 8010 Graz, Austria

We’re proud to share that 𝗣𝗿𝗼𝗳. 𝗗𝗿. Philipp Jost , Scientific Founder of Cycuria Therapeutics , is featured in Drug Target Review discussing innovative strategies to address relapse in acute myeloid leukemia ( AML ).

In the article “𝙏𝙖𝙧𝙜𝙚𝙩𝙞𝙣𝙜 𝙞𝙣𝙛𝙡𝙖𝙢𝙢𝙖𝙩𝙤𝙧𝙮 𝙘𝙚𝙡𝙡 𝙙𝙚𝙖𝙩𝙝 𝙩𝙤 𝙩𝙖𝙘𝙠𝙡𝙚 𝙧𝙚𝙡𝙖𝙥𝙨𝙚 𝙞𝙣 𝘼𝙈𝙇”, Prof. Jost highlights how our synthetic cytokine-based approach leverages inflammatory cell death pathways to selectively suppress leukemic stem and progenitor cells while preserving healthy hematopoiesis — a mechanistic strategy that underpins our lead therapeutic program, 𝗖𝗨𝗥-𝟭𝟬𝟭.

👉 Read the full article: HERE

Share:

More Posts

At Cycuria, we are dedicated to developing novel cytokine-based therapies to dramatically improve outcomes for patients living with cancer, offering hope where traditional treatments have fallen short.